TABLE 5.
GMTs and 95% CIs for SBA titers and the percentage of vaccine responders after vaccination with a hexavalent meningococcal OMV vaccine
| Strain | Relation to vaccine VRsb | GMT (95% CI) | % of children with 4-fold increase in titer |
|---|---|---|---|
| P1.7-2,13-2 I | NC, VR1 = i, VR2 = v | 8.0 (4.6-13.9) | 56 |
| P1.7-2,13-2 II | NC, VR1 = i, VR2 = v | 2.6 (1.5-4.5) | 23 |
| P1.7-2,13-1 | NC, VR1 = i, VR2 = v | 59.6 (33.8-105.0) | 92 |
| P1.7-2,13-2 | NC, VR1 = i, VR2 = v | 3.2 (1.8-5.8) | 28 |
| P1.7-1,1 | VR1 = v, VR2 = u | 2.2 (1.4-3.5) | 23 |
| P1.21,16 | VR1 = u, VR2 = i | 6.7 (3.8-11.9) | 58 |
| P1.7-2,9 | VR1 = i, VR2 = u | 4.3 (2.6-7.2) | 36 |
| P1.7-2,16 | NC, VR1 = i, VR2 = i | 7.1 (4.4-11.4) | 54 |
| P1.7-2,2 | NC, VR1 = i, VR2 = v | 8.8 (5.2-15.0) | 60 |
| P1.7-2,13 | NC, VR1 = i, VR2 = i | 5.3 (3.6-7.7) | 40 |
| P1.7,16 H44/76 | Vaccine strain | 15.8 (10.1-24.5) | 84 |
| P1.7-2,4 TR4 | Vaccine strain | 5.7 (3.8-8.4) | 64 |
| P1.12-1,13 TR1213 | Vaccine strain | 15.6 (10.1-24.0) | 88 |
a
All data are from trial I post booster (n = 50).
b
Abbreviations: NC, new combination; of vaccine VRs; i, identical to vaccine VR; v, variant of vaccine VR; u, unrelated to any of the vaccine VRs.